Li Long

Li Long, MD, Ph.D., is the Vice President of Clinical Development – Immunology, and is a surgeon and tumor biologist by training. Prior to joining Kezar, he was the Sr. Director of Clinical Development at Principia Biopharma where he led the clinical studies of the selective BTK inhibitor, rilzabrutinib, for the treatment of IgG4-related disease, and the FGFR 1-4 Kinase inhibitor, PRN1371, for the treatment of solid tumors. Before Principia, Li spent 20 years in the field of Translational Medicine at Eureka Therapeutics, KBP Biosciences, FivePrime Therapeutics, Novartis, Chiron, Rhône-Poulenc Rorer/Aventis.

Li received his MD degree in China and practiced for 8 years in general surgery. He obtained his Ph.D. degree in tumor biology from McGill University, Montreal, Canada and completed postdoctoral training in Cancer Vaccine at Albert Einstein College of Medicine, New York.